Wealth Enhancement Advisory Services LLC Purchases 394 Shares of Illumina, Inc. (NASDAQ:ILMN)

Wealth Enhancement Advisory Services LLC raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,170 shares of the life sciences company’s stock after purchasing an additional 394 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Illumina were worth $2,369,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its holdings in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares in the last quarter. TD Private Client Wealth LLC grew its position in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after acquiring an additional 141 shares during the last quarter. Massmutual Trust Co. FSB ADV raised its stake in shares of Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of Illumina in the 2nd quarter worth approximately $61,000. Finally, Private Trust Co. NA boosted its stake in shares of Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 212 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on ILMN. TD Cowen lifted their target price on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. Stephens increased their target price on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Barclays raised their price target on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Robert W. Baird increased their price objective on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Eight investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $165.63.

Illumina Trading Down 5.4 %

ILMN opened at $136.48 on Wednesday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The stock’s fifty day moving average is $140.55 and its two-hundred day moving average is $133.10. The company has a market capitalization of $21.65 billion, a P/E ratio of -13.70 and a beta of 1.11. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same period last year, the business posted $0.33 EPS. The business’s revenue was down 3.5% compared to the same quarter last year. Analysts forecast that Illumina, Inc. will post 4.11 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.